Phase 2, randomized multi oral immunotherapy with omalizumab 'real life' study.
Saved in:
| Title: | Phase 2, randomized multi oral immunotherapy with omalizumab 'real life' study. |
|---|---|
| Authors: | Sindher SB; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA., Kumar D; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA., Cao S; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA., Purington N; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Quantitative Sciences Unit, Stanford University, Stanford, California, USA., Long A; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA., Sampath V; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA., Zedeck SS; University of California, Los Angeles, California, USA.; Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Los Angeles, California, USA., Woch MA; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA., Garcia-Lloret M; University of California, Los Angeles, California, USA.; Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Los Angeles, California, USA., Chinthrajah RS; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA. |
| Source: | Allergy [Allergy] 2022 Jun; Vol. 77 (6), pp. 1873-1884. Date of Electronic Publication: 2022 Jan 24. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 7804028 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1398-9995 (Electronic) Linking ISSN: 01054538 NLM ISO Abbreviation: Allergy Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1398-9995 |
|---|---|
| DOI: | 10.1111/all.15217 |
